ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
|Articles|September 1, 2006
- ONCOLOGY Vol 20 No 10
- Volume 20
- Issue 10
Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies
Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies
Advertisement
Download the wall chart of Skin-Related Toxicities of Targeted Therapies as a PDF.
Articles in this issue
about 20 years ago
Complete Guide to Colorectal Cancerabout 20 years ago
Decitabine Receives US Orphan Drug Designation for AMLabout 20 years ago
New Questions About Transplantation in Multiple Myeloma: Review 1about 20 years ago
FDA Approves Drug Combination for Ovarian Cancer Recurrenceabout 20 years ago
Stage III Lung Cancer: Two or Three Modalities? Review 1Advertisement
Related to this article
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5